|
|
Post by kc on Aug 31, 2014 14:32:11 GMT -5
I came across this company that MannKind made a License agreement on some cancer drugs. This is the first time I have seen this bit it shows that there are other potential drugs int the pipeline not even tied to Technosphere. Has anybody ever heard of this company Tolero Pharmaceutical. www.businessweek.com/ap/2012-04-30/mannkind-licenses-drugs-to-tolero-for-up-to-130mNEW YORK (AP) — Diabetes drug developer MannKind Corp. said Monday that it is licensing a group of experimental drugs to Tolero Pharmaceuticals Inc. in a deal that could be worth more than $130 million. MannKind said the drug candidates are being studied as treatments for blood cancers and inflammatory diseases. Tolero will have worldwide rights to develop the drugs. Tolero will pay MannKind as the drugs advance through clinical development and regulatory review and reach sales targets if they are approved. MannKind said it will also receive licensing payments and royalties on any sales. The Valencia, Calif., company will have the right to require the drugs after early-stage clinical testing is complete. Tolero is based in Salt Lake City, and it develops treatments for cancer and other diseases. www.toleropharmaceuticals.com/press04302012.htmlTolero and MannKind Sign Collaboration and License Agreement Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Malignancies and Inflammatory Diseases.
SALT LAKE CITY, UT & VALENCIA, CA - (BUSINESS WIRE) - April 30, 2012 - Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, and MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes and cancer, today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases. Under the terms of the agreement, Tolero will pay MannKind upfront and milestone payments linked to the development, approval and commercialization of products, for total potential upfront and milestone payments of approximately $130 million. MannKind will also receive tiered royalties on sales of products and a percentage of sublicensing revenue. In addition, MannKind has an option to re-acquire the rights to the program at pre-specified terms until 60 days after the conclusion of the first Phase 1 study. If MannKind exercises this option, then MannKind would assume responsibility for developing and commercializing products and Tolero would become entitled to receive the milestone payments, royalties and sublicensing revenues specified in the agreement. "We are really excited about this opportunity and pleased to be working with an experienced drug development team at MannKind that is passionate about moving this program forward. BTK currently represents one of the most exciting therapeutic targets in oncology, and we feel that our collaborative approach to targeting BTK may uncover some novel utilities not yet fully realized," said Dallin Anderson, Chairman and President of Tolero. Dr. David Bearss, Founder of Tolero, added, "BTK has already been demonstrated to be a validated clinical target in multiple disease settings. We believe that MannKind has developed a series of novel compounds with unique mechanisms of action that may lead to important treatments for cancer and autoimmune diseases, such as rheumatoid arthritis. We are excited to be a strategic partner with MannKind." About Tolero Pharmaceuticals Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has used its innovative drug development platform to create a diverse portfolio of drug candidates targeting several cancer-associated cellular pathways. Tolero Pharmaceuticals is a privately held company founded in 2011 and headquartered in Salt Lake City, Utah. I wonder how many other investments that MannKind has in the drug pipeline that might eventually make it to Market. |
|
|
|
Post by mannmade on Aug 31, 2014 16:04:51 GMT -5
Yes KC I have referenced this deal in a couple of my previous posts when discussing assets and valuation. Mannkind Corp once had a very robust oncology research and development program. Unfortunately they had to shutter it after the second crl in order to cut costs so they could focus on getting Afrezza to market. It is my understanding that their oncology R&D program will remain shuttered for the time being.
But I can tell you as others may already know as well, that they have several products in the pipeline that are both Technosphere related and non technosphere related as follows:
1.) Cricket Flu Vaccine
2.) Migrane Treatment
3.) Non-Opiate Pain Substitue that you can take as much as you want for as long as you need without overdosing or getting addicted. (The Holy Grail for drugs as far as I am concerned in terms of sales potential) Being developed with a company in Torrey Pines.
4.) Basal Insulin Patch
Am sure there are other Technosphere partnerships on the way and others on this board likely know more than me about such activities but hope this helps...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 31, 2014 17:17:52 GMT -5
Not so sure about the "Basal Insulin Patch"?
|
|
|
|
Post by liane on Aug 31, 2014 18:09:13 GMT -5
kc,
This was well publicized at the time. I don't believe there was much upfront money to MNKD involved.
|
|
|
|
Post by zieg on Sept 1, 2014 2:45:43 GMT -5
|
|
|
|
Post by mnholdem on Sept 1, 2014 6:58:18 GMT -5
There is another patent for development of inhaled antidotes that can be used in chemical warfare and/or biological attacks. The target customers would be U.S. Armed Services, Israel, NATO forces, etc.
|
|
|
|
Post by kc on Sept 1, 2014 8:03:55 GMT -5
Good to peel back the MNKD onion. technovax.com/TechnoVax_LSHVS13.pdfThere is another patent for development of inhaled antidotes that can be used in chemical warfare and/or biological attacks. The target customers would be U.S. Armed Services, Israel, NATO forces, etc. |
|
|
|
Post by kc on Sept 1, 2014 11:02:10 GMT -5
Good post by Kevinmik on YMB.
Mannkind Has 5 Licensing Deals We Know Of - How Many More Are Being Worked On ?
1) Technovax Inc. - Inhaled Powder or Reconstituted, Influenza Vaccine VLP-based Respiratory Syncytial Virus (RSV) Vaccine. No announcement made by Mannkind about this arrangement or financial terms revealed.
2) Telero Pharma - MannKind says it could get $130 million and royalties & licensing fees after licensing drug candidates to Tolero. MannKind said the drug candidates are being studied as treatments for blood cancers and inflammatory diseases.
3) Rose Pharma - 07/03/14 Mannkind & Rose Pharma A/S Joint Patent Application Inhaled GLP-1 Treating IBS &/Or Functional Dyspepsia. No announcement made by Mannkind about this arrangement or financial terms revealed.
4) Colby Pharma - . MannKind have entered a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s MKC1106 active immunotherapy programs. These programs are currently being developed for the treatment of melanoma, prostate, hematological disorders and other cancers.MannKind will receive an upfront payment and milestones related to the development, approval and commercialization of products, with potential payments totaling $140 million. MannKind will also receive royalties on sales.
5) Sanofi - Mannkind global licensing deal to include $150 million upfront payment, additional $775 million in milestone payment, profit sharing arrangement on all global sales 65/35 & future licensing rights for inhaled GLP-1 for diabetes.
Now that Technosphere has been approved in the use of Afrezza that will reach millions of diabetes patients in the United States and eventually around the world, this very important and paradigm changing technology could and should have a line forming at Mannkind to sign additional collaboration deals.
we also need to add Torrey Pines to this list.
|
|
|
|
Post by 1 percenter on Sept 1, 2014 11:47:48 GMT -5
The only deal that has actually put money in MNKD's pocket has been Sanofi. The other deals, especially Tolero and Colby never gave a figure as to what upfront money was given. The reason why is none was ever given. I am not sure why MNKD was dishonest about those deals. I looked a while back and never say any movement by either pharma on what they got from Mannkind. It would appear they are just holding the compounds until Mannkind can jump back in with funding. This management team really knows what buttons to push to frustrate their stockholders.
|
|
|
|
Post by kc on Sept 1, 2014 13:09:52 GMT -5
Far stretch with probably no basis. So don't shoot me for over reaching or dreaming of ties to MannKind.Is Technovax working with NIH on a vaccine on Ebola? I came across this link. www.vaccinenation.org/2014/06/05/technovax-awarded-nih-grant-develop-vlp-based-respiratory-syncytial-virus-rsv-vaccine/. I know that RSV is not the same as Ebola. But just research what Technovax is working regard all types of vaccines. another interesting link... www.ajns.com/old%20websites/www.technovax.com/market.html. (Old Technovax web site) Annual vaccine sales worldwide are projected to reach about $18 billon and the vaccine market is projected to increase 12% per year. Introduction of safe and efficacious novel vaccines manufactured with the most cost-effective technology will have significant commercial advantage and will potentially dominate the marketplace. Potential Vaccine Targets Where VLP Technology Could Be Utilized Primary Targets Influenza A and B viruses Vaccine available, dated technology, Cumbersome manufacturing process Respiratory Syncytial Virus (RSV). No vaccine available Parainfluenza virus (PIV) No vaccine available Metapneumovirus No vaccine available Secondary TargetsHepatitis C virus No vaccine available West Nile Virus No vaccine available Coronavirus (SARS) No vaccine available Viral Hemorrhagic Fevers:
Dengue, Ebola, etc.
No vaccine availableCancer Vaccine Targets No vaccine available
|
|
|
|
Post by 4Balance on Sept 4, 2014 3:23:57 GMT -5
I came across this company that MannKind made a License agreement on some cancer drugs. This is the first time I have seen this bit it shows that there are other potential drugs int the pipeline not even tied to Technosphere. Has anybody ever heard of this company Tolero Pharmaceutical. www.toleropharmaceuticals.com/press04302012.htmlTolero and MannKind Sign Collaboration and License Agreement Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Malignancies and Inflammatory Diseases.
SALT LAKE CITY, UT & VALENCIA, CA - (BUSINESS WIRE) - April 30, 2012 - Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, and MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes and cancer, today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases. Under the terms of the agreement, Tolero will pay MannKind upfront and milestone payments linked to the development, approval and commercialization of products, for total potential upfront and milestone payments of approximately $130 million. MannKind will also receive tiered royalties on sales of products and a percentage of sublicensing revenue. In addition, MannKind has an option to re-acquire the rights to the program at pre-specified terms until 60 days after the conclusion of the first Phase 1 study. If MannKind exercises this option, then MannKind would assume responsibility for developing and commercializing products and Tolero would become entitled to receive the milestone payments, royalties and sublicensing revenues specified in the agreement. "We are really excited about this opportunity and pleased to be working with an experienced drug development team at MannKind that is passionate about moving this program forward. BTK currently represents one of the most exciting therapeutic targets in oncology, and we feel that our collaborative approach to targeting BTK may uncover some novel utilities not yet fully realized," said Dallin Anderson, Chairman and President of Tolero. Dr. David Bearss, Founder of Tolero, added, "BTK has already been demonstrated to be a validated clinical target in multiple disease settings. We believe that MannKind has developed a series of novel compounds with unique mechanisms of action that may lead to important treatments for cancer and autoimmune diseases, such as rheumatoid arthritis. We are excited to be a strategic partner with MannKind." About Tolero Pharmaceuticals Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has used its innovative drug development platform to create a diverse portfolio of drug candidates targeting several cancer-associated cellular pathways. Tolero Pharmaceuticals is a privately held company founded in 2011 and headquartered in Salt Lake City, Utah. I scoured the article for evidence of a Technosphere application...came up empty. Do we think the BTK Inhibitors WOULD ride Technosphere?? If so, do we have a source for that connection? |
|
|
|
Post by mnholdem on Sept 4, 2014 11:14:46 GMT -5
Good post by Kevinmik on YMB. Mannkind Has 5 Licensing Deals We Know Of - How Many More Are Being Worked On ? . . . 5) Sanofi - Mannkind global licensing deal to include $150 million upfront payment, additional $775 million in milestone payment, profit sharing arrangement on all global sales 65/35 & future licensing rights for inhaled GLP-1 for diabetes. Now that Technosphere has been approved in the use of Afrezza that will reach millions of diabetes patients in the United States and eventually around the world, this very important and paradigm changing technology could and should have a line forming at Mannkind to sign additional collaboration deals. we also need to add Torrey Pines to this list. I replied to kev's post, and pointed out that Sanofi rights for GLP-1 is pure speculation which grew from Al's remarks during a recent conference call. "New process" is not the same as "new drug" and even if that's what Al meant, there has been no further clarification by Matt or others regarding Sanofi's rights to an inhaled GLP-1.
|
|
|
|
Post by mannmade on Sept 4, 2014 11:34:18 GMT -5
Good post by Kevinmik on YMB. Mannkind Has 5 Licensing Deals We Know Of - How Many More Are Being Worked On ? . . . 5) Sanofi - Mannkind global licensing deal to include $150 million upfront payment, additional $775 million in milestone payment, profit sharing arrangement on all global sales 65/35 & future licensing rights for inhaled GLP-1 for diabetes. Now that Technosphere has been approved in the use of Afrezza that will reach millions of diabetes patients in the United States and eventually around the world, this very important and paradigm changing technology could and should have a line forming at Mannkind to sign additional collaboration deals. we also need to add Torrey Pines to this list. I replied to kev's post, and pointed out that Sanofi rights for GLP-1 is pure speculation which grew from Al's remarks during a recent conference call. "New process" is not the same as "new drug" and even if that's what Al meant, there has been no further clarification by Matt or others regarding Sanofi's rights to an inhaled GLP-1.
Actually as I recall the one thing that Sanofi has a rt of first refusal on outside of Afrezza is use of technosphere with a GLP-1 |
|
|
|
Post by brentie on Sept 4, 2014 11:55:12 GMT -5
Matthew Pfeffer - CFO In that regard, I've been asked this a couple of times on the phone, so probably clarify it, because people will say what rights in those other areas do Sanofi have? They do have a right of first negotiation if we were to take a formulation of inhalable GLP-1 forward. But they have not rights to those -- any other products beyond that. So, I can't say we would mind talking to them about them when they get to the point when that’s appropriate. But under the current agreement, the only future potential right they have is on the GLP-1. seekingalpha.com/article/2412135-mannkinds-mnkd-ceo-alfred-mann-on-q2-2014-results-earnings-call-transcript?find=glp&all=false |
|
|
|
Post by liane on Sept 4, 2014 17:41:01 GMT -5
brentie - Love the new Avatar (cat surrounded by numerous golden pups). Hope you keep it for a while!  |
|
